[HTML][HTML] Interleukin-1 receptor-associated kinase-3 is a key inhibitor of inflammation in obesity and metabolic syndrome

M Hulsmans, B Geeraert, D De Keyzer, A Mertens… - PloS one, 2012 - journals.plos.org
M Hulsmans, B Geeraert, D De Keyzer, A Mertens, M Lannoo, B Vanaudenaerde…
PloS one, 2012journals.plos.org
Background Visceral obesity is associated with the rising incidence of type 2 diabetes and
metabolic syndrome. Low-grade chronic inflammation and oxidative stress synergize in
obesity and obesity-induced disorders. Objective We searched a cluster of molecules that
support interactions between these stress conditions in monocytes. Methods RNA
expressions in blood monocytes of two independent cohorts comprising 21 and 102 obese
persons and 46 age-matched controls were determined by microarray and independently …
Background
Visceral obesity is associated with the rising incidence of type 2 diabetes and metabolic syndrome. Low-grade chronic inflammation and oxidative stress synergize in obesity and obesity-induced disorders.
Objective
We searched a cluster of molecules that support interactions between these stress conditions in monocytes.
Methods
RNA expressions in blood monocytes of two independent cohorts comprising 21 and 102 obese persons and 46 age-matched controls were determined by microarray and independently validated by quantitative RT-PCR analysis. The effect of three-month weight loss after bariatric surgery was determined. The effect of RNA silencing on inflammation and oxidative stress was studied in human monocytic THP-1 cells.
Results
Interleukin-1 receptor-associated kinase-3 (IRAK3), key inhibitor of IRAK/NFκB-mediated chronic inflammation, is downregulated in monocytes of obese persons. Low IRAK3 was associated with high superoxide dismutase-2 (SOD2), a marker of mitochondrial oxidative stress. A comparable expression profile was also detected in visceral adipose tissue of the same obese subjects. Low IRAK3 and high SOD2 was associated with a high prevalence of metabolic syndrome (odds ratio: 9.3; sensitivity: 91%; specificity: 77%). By comparison, the odds ratio of high-sensitivity C-reactive protein, a widely used marker of systemic inflammation, was 4.3 (sensitivity: 69%; specificity: 66%). Weight loss was associated with an increase in IRAK3 and a decrease in SOD2, in association with a lowering of systemic inflammation and a decreasing number of metabolic syndrome components. We identified the increase in reactive oxygen species in combination with obesity-associated low adiponectin and high glucose and interleukin-6 as cause of the decrease in IRAK3 in THP-1 cells in vitro.
Conclusion
IRAK3 is a key inhibitor of inflammation in association with obesity and metabolic syndrome. Our data warrant further evaluation of IRAK3 as a diagnostic and prognostic marker, and as a target for intervention.
PLOS